Anti-Human/Mouse EGFR Antibody (7A7) ia an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab. Anti-Human/Mouse EGFR Antibody (7A7) fails to induce tumor regression in the HPV38 tumor model where EGFR is not expressed in mice. Anti-Human/Mouse EGFR Antibody (7A7) can be used in EGFR -expressing HPV38 tumor-related studies [1].
In Vivo, 7A7 (56 μg; i.v.; every three days) does not reduce tumour growth or improve survival in C57BL/6 mice bearing subcutaneous TC-1 squamous cell carcinoma tumours[1].
In Vitro, 7A7 (60 mins at room temperature) exhibits non-specific intracellular and plasma membrane staining in EGFR-positive A431, 3T3-L1, and HPV38 cells, and EGFR-negative TC-1 cells, indicating it does not specifically detect native EGFR via immunofluorescence[1].
References:
[1]. He X, et al. Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab. Oncotarget. 2018 Jan 13;9(15):12250-12260.
In Vivo, 7A7 (56 μg; i.v.; every three days) does not reduce tumour growth or improve survival in C57BL/6 mice bearing subcutaneous TC-1 squamous cell carcinoma tumours[1].
In Vitro, 7A7 (60 mins at room temperature) exhibits non-specific intracellular and plasma membrane staining in EGFR-positive A431, 3T3-L1, and HPV38 cells, and EGFR-negative TC-1 cells, indicating it does not specifically detect native EGFR via immunofluorescence[1].
References:
[1]. He X, et al. Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab. Oncotarget. 2018 Jan 13;9(15):12250-12260.